{
  "guideline": {
    "id": "PA166328689",
    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Fosphenytoin - CYP2C9",
    "objCls": "PGx Association",
    "source": "FDA",
    "version": 0,
    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328689",
    "relatedChemicals": [
      {
        "id": "PA164746820",
        "name": "fosphenytoin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166324225",
      "name": "Recommendation Annotation PA166324225",
      "population": "CYP2C9 intermediate or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337684,
        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk (central nervous system toxicity). Consider starting at the lower end of the dosage range and monitor serum concentrations. Refer to FDA labeling for specific dosing recommendations. Carriers of CYP2C9*3 alleles may be at increased risk of severe cutaneous adverse reactions. Consider avoiding fosphenytoin as an alternative to carbamazepine in patients who are CYP2C9*3 carriers. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": "1.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324223",
      "name": "Recommendation Annotation PA166324223",
      "population": "CYP2C9 intermediate or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337682,
        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk (central nervous system toxicity). Consider starting at the lower end of the dosage range and monitor serum concentrations. Refer to FDA labeling for specific dosing recommendations. Carriers of CYP2C9*3 alleles may be at increased risk of severe cutaneous adverse reactions. Consider avoiding fosphenytoin as an alternative to carbamazepine in patients who are CYP2C9*3 carriers. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324224",
      "name": "Recommendation Annotation PA166324224",
      "population": "CYP2C9 intermediate or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337683,
        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk (central nervous system toxicity). Consider starting at the lower end of the dosage range and monitor serum concentrations. Refer to FDA labeling for specific dosing recommendations. Carriers of CYP2C9*3 alleles may be at increased risk of severe cutaneous adverse reactions. Consider avoiding fosphenytoin as an alternative to carbamazepine in patients who are CYP2C9*3 carriers. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324222",
      "name": "Recommendation Annotation PA166324222",
      "population": "CYP2C9 intermediate or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337681,
        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk (central nervous system toxicity). Consider starting at the lower end of the dosage range and monitor serum concentrations. Refer to FDA labeling for specific dosing recommendations. Carriers of CYP2C9*3 alleles may be at increased risk of severe cutaneous adverse reactions. Consider avoiding fosphenytoin as an alternative to carbamazepine in patients who are CYP2C9*3 carriers. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [],
  "version": "2024-03-08-14-34"
}